Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ET-01 (Entheos Labs)
- Development stage
- Preclinical
- Lead developer
- Entheos Labs
- Modality
- Small Molecules
01
Overview
ET-01 is a synthetic small molecule derivative of a natural product being developed by Entheos Labs as a potent 5-hydroxytryptamine receptor 2A (5HT2A) agonist. Designed to promote neuroplasticity, ET-01 is the lead asset in Entheos Labs' pipeline for the treatment of various mental health conditions, including mood disorders, anxiety disorders, trauma-based disorders, and substance use disorders. The drug is being developed using a novel formulation and delivery method, leveraging an AI-powered drug discovery platform in collaboration with Massachusetts General Hospital (MGH) to optimize safety, tolerability, and user experience.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on ET-01 (Entheos Labs).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ET-01 (Entheos Labs).